DoctorSolar Posted July 6, 2011 Author Report Share Posted July 6, 2011 And this report from our man Patrick Cox: NanoViricides Contracts With BCG for FDA Submission Dear Breakthrough Technology Alert Readers, I'm keeping this short today. Fortunately, I've got good news regarding NanoViricides Inc. (OTCBB: NNVC). With most other companies, the hiring of even a top firm to help with the FDA submission process might not be such a big thing. NanoViricides, however, is in a unique position. The reason, of course, is that the company has the only technology that can directly shut down viruses in the bloodstream. It doesn't require any kind of immune system tweak and it involves no drugs, in the common sense of the word. At all. In a word, it is historic. While other companies are working on various ways to vaccinate for viruses, NanoViricides' simple nanotech approach to influenza, dengue fever, Ebola and a host of other viruses is fundamentally mechanical. Signaling ligands are attached to polymer nanotech structures called micelles. These are the nanoviricides that lure viruses inside them, where they are trapped and harmlessly eliminated from the system. I'm still amazed that the legacy media hasn't caught on to this astonishing technology, which is the most revolutionary implementation of nanomedicine to date. Nevertheless, the company's agreement with the renowned Biologics Consulting Group Inc. (BCG) to assist with FDA approval is a big deal. Those of you who have been with me for a while remember when multiple analysts were claiming that NanoViricides was a scam and that I was part of the scam. In fact, I'm pretty sure that many of those making such claims were actually part of a scam themselves, trying their best to drive the stock price down, either to buy shares cheap or to short the company. We're seeing this same pattern of short attack on many of our companies right now. BioTime (AMEX: BTX) and Star Scientific (NASDAQ: CIGX) are most notable for the savagery and dishonesty of the attacks. Regardless, the recent spectacular validation of NanoViricides' FluCide in animals, combined with the BCG agreement, puts the company on track to billion-dollar status. The use of BCG, by the way, is important because they specialize in biologics, which often face different regulatory issues than traditional drugs. Remember also that NanoViricides has recently signed an agreement to rent and possibly acquire the structure for their own cGMP (current good manufacturing practice) facility. If you'd like an overview of this government-required facility, check this out. Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now